COMBINATION OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CORONAVIRUS DISEASES
A method of treatment for an individual infected with COVID-19 which comprises: - providing a first compound and a second compound, individually selected from the group consisting of: Epidermal Growth Factor Receptor (EGFR) Inhibitors; Serine Threonine Kinase Inhibitors; Vascular Endothelial Growth...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HNIK, PETER CORMIER, STEPHANIA ADER, ALLAN CHO, TIFFANY WASAN, KISHOR M BRYLINSKI, MICHAL ABRAMOV, JULIA BESS, ADAM GOULD, JANET JELESIJEVI, TOMISLAV GRIGGS, NICHOLAS MUKHOPADHYAY, SUPRATIK GALLIANO, CHRIS BERGLIND, FREJ KNUT GOSTA |
| description | A method of treatment for an individual infected with COVID-19 which comprises: - providing a first compound and a second compound, individually selected from the group consisting of: Epidermal Growth Factor Receptor (EGFR) Inhibitors; Serine Threonine Kinase Inhibitors; Vascular Endothelial Growth Factor (VEGF) inhibitors; and STAT3 Inhibitors, and - administering to said individual a sufficient amount of said first compound and a sufficient amount of said second compound to produce a therapeutic effect against COVID-19, wherein said first compound and said compound are not from the same group and are not the same compound. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3100154A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3100154A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3100154A13</originalsourceid><addsrcrecordid>eNqNi0EKwkAMRWfjQtQ75AJCh-oBpmNKgzSBSRRclVLGlWih3h9H8ACu_uPx_tqlKH1DHIyEQVqwWxIlRjgXqQjEHTVkkrQgWIdgCYP1yPbNoyThcKV0UTiRYrno1q3u42PJu99uHLRosdvn-TXkZR6n_MzvIYbaV5U_HoKv_0g-kvwvQw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMBINATION OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CORONAVIRUS DISEASES</title><source>esp@cenet</source><creator>HNIK, PETER ; CORMIER, STEPHANIA ; ADER, ALLAN ; CHO, TIFFANY ; WASAN, KISHOR M ; BRYLINSKI, MICHAL ; ABRAMOV, JULIA ; BESS, ADAM ; GOULD, JANET ; JELESIJEVI, TOMISLAV ; GRIGGS, NICHOLAS ; MUKHOPADHYAY, SUPRATIK ; GALLIANO, CHRIS ; BERGLIND, FREJ KNUT GOSTA</creator><creatorcontrib>HNIK, PETER ; CORMIER, STEPHANIA ; ADER, ALLAN ; CHO, TIFFANY ; WASAN, KISHOR M ; BRYLINSKI, MICHAL ; ABRAMOV, JULIA ; BESS, ADAM ; GOULD, JANET ; JELESIJEVI, TOMISLAV ; GRIGGS, NICHOLAS ; MUKHOPADHYAY, SUPRATIK ; GALLIANO, CHRIS ; BERGLIND, FREJ KNUT GOSTA</creatorcontrib><description>A method of treatment for an individual infected with COVID-19 which comprises: - providing a first compound and a second compound, individually selected from the group consisting of: Epidermal Growth Factor Receptor (EGFR) Inhibitors; Serine Threonine Kinase Inhibitors; Vascular Endothelial Growth Factor (VEGF) inhibitors; and STAT3 Inhibitors, and - administering to said individual a sufficient amount of said first compound and a sufficient amount of said second compound to produce a therapeutic effect against COVID-19, wherein said first compound and said compound are not from the same group and are not the same compound.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220520&DB=EPODOC&CC=CA&NR=3100154A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220520&DB=EPODOC&CC=CA&NR=3100154A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HNIK, PETER</creatorcontrib><creatorcontrib>CORMIER, STEPHANIA</creatorcontrib><creatorcontrib>ADER, ALLAN</creatorcontrib><creatorcontrib>CHO, TIFFANY</creatorcontrib><creatorcontrib>WASAN, KISHOR M</creatorcontrib><creatorcontrib>BRYLINSKI, MICHAL</creatorcontrib><creatorcontrib>ABRAMOV, JULIA</creatorcontrib><creatorcontrib>BESS, ADAM</creatorcontrib><creatorcontrib>GOULD, JANET</creatorcontrib><creatorcontrib>JELESIJEVI, TOMISLAV</creatorcontrib><creatorcontrib>GRIGGS, NICHOLAS</creatorcontrib><creatorcontrib>MUKHOPADHYAY, SUPRATIK</creatorcontrib><creatorcontrib>GALLIANO, CHRIS</creatorcontrib><creatorcontrib>BERGLIND, FREJ KNUT GOSTA</creatorcontrib><title>COMBINATION OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CORONAVIRUS DISEASES</title><description>A method of treatment for an individual infected with COVID-19 which comprises: - providing a first compound and a second compound, individually selected from the group consisting of: Epidermal Growth Factor Receptor (EGFR) Inhibitors; Serine Threonine Kinase Inhibitors; Vascular Endothelial Growth Factor (VEGF) inhibitors; and STAT3 Inhibitors, and - administering to said individual a sufficient amount of said first compound and a sufficient amount of said second compound to produce a therapeutic effect against COVID-19, wherein said first compound and said compound are not from the same group and are not the same compound.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi0EKwkAMRWfjQtQ75AJCh-oBpmNKgzSBSRRclVLGlWih3h9H8ACu_uPx_tqlKH1DHIyEQVqwWxIlRjgXqQjEHTVkkrQgWIdgCYP1yPbNoyThcKV0UTiRYrno1q3u42PJu99uHLRosdvn-TXkZR6n_MzvIYbaV5U_HoKv_0g-kvwvQw</recordid><startdate>20220520</startdate><enddate>20220520</enddate><creator>HNIK, PETER</creator><creator>CORMIER, STEPHANIA</creator><creator>ADER, ALLAN</creator><creator>CHO, TIFFANY</creator><creator>WASAN, KISHOR M</creator><creator>BRYLINSKI, MICHAL</creator><creator>ABRAMOV, JULIA</creator><creator>BESS, ADAM</creator><creator>GOULD, JANET</creator><creator>JELESIJEVI, TOMISLAV</creator><creator>GRIGGS, NICHOLAS</creator><creator>MUKHOPADHYAY, SUPRATIK</creator><creator>GALLIANO, CHRIS</creator><creator>BERGLIND, FREJ KNUT GOSTA</creator><scope>EVB</scope></search><sort><creationdate>20220520</creationdate><title>COMBINATION OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CORONAVIRUS DISEASES</title><author>HNIK, PETER ; CORMIER, STEPHANIA ; ADER, ALLAN ; CHO, TIFFANY ; WASAN, KISHOR M ; BRYLINSKI, MICHAL ; ABRAMOV, JULIA ; BESS, ADAM ; GOULD, JANET ; JELESIJEVI, TOMISLAV ; GRIGGS, NICHOLAS ; MUKHOPADHYAY, SUPRATIK ; GALLIANO, CHRIS ; BERGLIND, FREJ KNUT GOSTA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3100154A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>HNIK, PETER</creatorcontrib><creatorcontrib>CORMIER, STEPHANIA</creatorcontrib><creatorcontrib>ADER, ALLAN</creatorcontrib><creatorcontrib>CHO, TIFFANY</creatorcontrib><creatorcontrib>WASAN, KISHOR M</creatorcontrib><creatorcontrib>BRYLINSKI, MICHAL</creatorcontrib><creatorcontrib>ABRAMOV, JULIA</creatorcontrib><creatorcontrib>BESS, ADAM</creatorcontrib><creatorcontrib>GOULD, JANET</creatorcontrib><creatorcontrib>JELESIJEVI, TOMISLAV</creatorcontrib><creatorcontrib>GRIGGS, NICHOLAS</creatorcontrib><creatorcontrib>MUKHOPADHYAY, SUPRATIK</creatorcontrib><creatorcontrib>GALLIANO, CHRIS</creatorcontrib><creatorcontrib>BERGLIND, FREJ KNUT GOSTA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HNIK, PETER</au><au>CORMIER, STEPHANIA</au><au>ADER, ALLAN</au><au>CHO, TIFFANY</au><au>WASAN, KISHOR M</au><au>BRYLINSKI, MICHAL</au><au>ABRAMOV, JULIA</au><au>BESS, ADAM</au><au>GOULD, JANET</au><au>JELESIJEVI, TOMISLAV</au><au>GRIGGS, NICHOLAS</au><au>MUKHOPADHYAY, SUPRATIK</au><au>GALLIANO, CHRIS</au><au>BERGLIND, FREJ KNUT GOSTA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMBINATION OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CORONAVIRUS DISEASES</title><date>2022-05-20</date><risdate>2022</risdate><abstract>A method of treatment for an individual infected with COVID-19 which comprises: - providing a first compound and a second compound, individually selected from the group consisting of: Epidermal Growth Factor Receptor (EGFR) Inhibitors; Serine Threonine Kinase Inhibitors; Vascular Endothelial Growth Factor (VEGF) inhibitors; and STAT3 Inhibitors, and - administering to said individual a sufficient amount of said first compound and a sufficient amount of said second compound to produce a therapeutic effect against COVID-19, wherein said first compound and said compound are not from the same group and are not the same compound.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3100154A1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | COMBINATION OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CORONAVIRUS DISEASES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T23%3A30%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HNIK,%20PETER&rft.date=2022-05-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3100154A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |